NCT00034892

CAFE Comparison of Atypicals in First Episode of Psychosis

Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: —
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 16 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.

Conditions

• Schizophrenia
• Psychotic Disorders
• Mental Health
• Mental Disorders

Interventions

Type	Name	Description
DRUG	Olanzapine, risperidone

Timeline

• Start date: 2002-03-01
• Primary completion: 2005-03-01
• Completion: 2005-03-01
• First posted: 2002-05-03
• Last updated: 2013-01-04

Locations

26 sites across 2 countries: United States, Canada